Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05958-8 ↗At a glance
Klinische Studie (Phase III) in Annals of Hematology, 2024. Written by Weijun Fu and 17 co-authors. Institution: Shanghai Changzheng Hospital, Shanghai, China. Major MEDLINE topics: Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Cited 7 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Janssen Research & Development, LLC.
Abstract (original language)
No hay resumen disponible.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Shanghai Changzheng Hospital, Shanghai, China.
- Seoul National University Bundang Hospital, Seongnam, South Korea.
- Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- First Hospital of Jilin University, Changchun, China.
- Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Funding
- Janssen Research & Development, LLC
Cite
APA
Fu, W., Bang, S. M., Huang, H., Kim, K., Li, W., An, G., Lee, J. J., Cai, Z., Jin, J., Wang, Y., Chim, C. S., Carson, R., Liu, R., Zhao, M., Chen, X., Cui, C., Hou, J., & Wang, J. (2024). Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Annals of Hematology. https://doi.org/10.1007/s00277-024-05958-8
Vancouver
Fu W, Bang SM, Huang H, Kim K, Li W, An G, et al. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Annals of Hematology. 2024. doi:10.1007/s00277-024-05958-8
BibTeX
@article{Fu2024,
author = {Fu, Weijun and Bang, Soo-Mee and Huang, Honghui and Kim, Kihyun and Li, Wei and An, Gang and Lee, Je-Jung and Cai, Zhen and Jin, Jie and Wang, Yafei and Chim, Chor Sang and Carson, Robin and Liu, Rui and Zhao, Man and Chen, Xi and Cui, Canchan and Hou, Jian and Wang, Jianxiang},
title = {Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05958-8}
}
EUVIMED